Total : 7 View more »
Nov 02, 2009 (Wall Street Horizon via COMTEX) --
ACADIA Pharmaceuticals Inc (ACAD)
Expected next earnings release: Announcement date: 11/9/2009 - After Market Earnings Quarter: Q3 Announcement Status: Verified
Expected next investor conference call information: Conference Call Date: 11/9/2009 Conference Call Time (ET): 5:00 PM Conference Call URL: http://ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-calendar
Tags: conference corporate earnings market pharmaceuticals
Companies: Acadia Pharmaceuticals, Inc. (ACAD)
Nov 03, 2009 (Wall Street Horizon via COMTEX) --
ACADIA Pharmaceuticals Inc (ACAD)
Expected next earnings release: Announcement date: 11/9/2009 - After Market Earnings Quarter: Q3 Announcement Status: Verified
Expected next investor conference call information: Conference Call Date: 11/9/2009 Conference Call Time (ET): 5:00 PM Conference Call URL: http://ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-calendar
Tags: conference corporate earnings market pharmaceuticals
Companies: Acadia Pharmaceuticals, Inc. (ACAD)
SAN DIEGO, Nov 02, 2009 (BUSINESS WIRE) --
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2009 on Monday, November 9, 2009, after the U.S. financial markets close. ACADIA's management will host a conference call and webcast on Monday, November 9, 2009, at 5:00 p.m. Eastern Time to discuss ACADIA's financial results and development programs.
The conference call may be accessed by dialing 866-510-0707 for participants in the U.S. or Canada and 617-597-5376 for international callers (reference passcode 92783090). A telephone replay of the conference call may be accessed through November 23, 2009 by dialing 888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for international callers (reference passcode 21130876). The conference call also will be webcast live on ACADIA's website, www.acadia-pharm.com, under the investors section and will be archived there until November 23, 2009.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA's product candidates include pimavanserin in Phase III for Parkinson's disease psychosis in collaboration with Biovail, a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, and AM-831 in IND-track development in collaboration with Meiji Seika Kaisha. All of the product candidates in ACADIA's pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA maintains a website at www.acadia-pharm.com to which ACADIA regularly posts copies of its press releases as well as additional information and through which interested parties can subscribe to receive email alerts.
SOURCE: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. Thomas H. Aasen, Vice President and Chief Financial Officer 858-558-2871
Tags: canada clinical conference disease email financial results indiana nasdaq pharmaceuticals pipeline technology track
Companies: Acadia Pharmaceuticals, Inc. (ACAD)
Oct 24, 2009 (Wall Street Horizon via COMTEX) --
ACADIA Pharmaceuticals Inc (ACAD)
Expected next earnings release: Announcement date: 11/5/2009 - After Market Earnings Quarter: Q3 Announcement Status: Unconfirmed
Tags: corporate earnings market pharmaceuticals
Companies: Acadia Pharmaceuticals, Inc. (ACAD)
Total : 20 View more »
A live webcast of ACADIA's presentation will be accessible on the company's website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through January 25, 2007. About ACADIA Pharmaceuticals
http://www.pharmacychoice.com/News/article.cfm?Article_ID=45105
Get the news that matters to you. Create your own customized news service that delivers the latest information directly to you. Plus you can view the most current press releases from Micromedex.
http://www.micromedex.com/pressroom/news_feeds/?story_ID=107500&category=1
ACP-104 is currently being evaluated in three clinical trials, all of which are being conducted in patients with schizophrenia and in collaboration with Professor Carol Tamminga, M.D.
http://www.pharmacychoice.com/News/article.cfm?Article_ID=16563
and 617-801-6888 for international callers (reference passcode 28397094). The conference call also will be webcast live on ACADIA's website, www.acadia-pharm.
http://www.pharmacychoice.com/News/article.cfm?Article_ID=10318
Total : 112 View more »
ACADIA Pharmaceuticals downgraded to "sell" www.newratings.com | Sep 1, 2009. NEW YORK, September 1 (newratings.com) - Analysts at Citigroup downgrade ACADIA Pharmaceuticals ...
http://www.zibb.com/all/theme/cq/ACADIA+Pharmaceuticals+Incorporated
Get the latest ACAD - ACADIA Pharmaceuticals Incorporated stock market performance data. TheStreet is the source for financial market news, trading stock, quotes, and personal ...
Find business news, business blogs, executive career advice, business travel, business culture, company & executive profiles.
http://www.portfolio.com/resources/company-profiles/ACADIA-Pharmaceuticals-Incorporated-7527
Michael Borer has served as a director of our company since September ... Top Executives at ACADIA Pharmaceuticals, Incorporated